Georgia Recurrent Miscarriage IVF: Eligibility & Process Explained

Opening: Doctor's Decision Logic

A patient with recurrent miscarriage, carrying records of three pregnancies all ceasing development between 8-10 weeks, enters the consultation room. As a reproductive specialist, the first distinction to make is: whether these miscarriages stem from the same cause. Embryonic chromosomal aneuploidy is the most common cause of early miscarriage, accounting for approximately 50% to 60%. If the patient's previous miscarriage tissue was sent for chromosomal karyotype analysis and the result was abnormal, then PGT-A is a clear indication. However, if the miscarriage tissue was not tested, or the karyotype was normal, a systematic investigation of uterine structure, endocrine, immune, and coagulation factors is necessary. Reproductive centers in Georgia possess complete testing capabilities for PGT technology, but patients must meet the corresponding medical indications.

Module A: Direct Answer to the Question

Direct Answer: IVF for Recurrent Miscarriage in Georgia

IVF is possible for recurrent miscarriage in Georgia, but the following medical conditions must be met:

• Cause of miscarriage is clear or highly suspected to be related to embryonic chromosomal abnormalities — confirmed by karyotype analysis of miscarriage tissue or karyotype testing of both partners.
• Woman's ovarian reserve is adequate — AMH ≥ 1.0 ng/mL, antral follicle count ≥ 6, sufficient to obtain an adequate number of eggs for embryo screening.
• No severe uterine structural abnormalities — or structural abnormalities have been corrected through hysteroscopic surgery (e.g., septum resection, adhesion lysis).
• No uncontrolled systemic diseases — such as severe autoimmune disease, uncorrected thyroid dysfunction, untreated antiphospholipid syndrome, etc.

Cases not suitable for direct IVF:

• Cause of miscarriage is uncorrected uterine anatomical abnormality (e.g., complete uterine septum, severe intrauterine adhesions).
• Presence of uncontrolled antiphospholipid syndrome or coagulation abnormalities, requiring prior immunotherapy and anticoagulation therapy.
• Woman's ovarian failure (AMH < 0.5 ng/mL, antral follicle count < 3), unable to obtain sufficient eggs for PGT.
• Genetic issues that PGT technology cannot resolve (e.g., certain mitochondrial diseases or rare genetic disorders requiring custom probes).

Module C: Doctor's Perspective

Reproductive Medicine Perspective: How Doctors View This Issue

From an evidence-based medicine standpoint, whether a patient with recurrent miscarriage chooses IVF and whether to perform PGT depends on the clarity of the etiology.

• Recurrent miscarriage caused by chromosomal abnormalities — PGT-A can significantly reduce the risk of another miscarriage, with live birth rates after euploid embryo transfer reaching 50% to 60%.
• Unexplained recurrent miscarriage — PGT-A does not improve live birth rates and may even reduce cumulative pregnancy rates due to the potential risks of embryo biopsy and embryo attrition. These patients should prioritize investigation of immune, coagulation, and uterine factors.
• One partner carries a chromosomal structural abnormality — such as balanced translocation, Robertsonian translocation, PGT-SR is a clear indication to select normal or balanced carrier embryos.

When seeing patients with recurrent miscarriage, reputable reproductive centers in Georgia will first require a systematic etiological workup rather than directly recommending IVF. This is a fundamental difference from some commercial intermediary agencies.

Module L: Interpretation of Key Tests

Key Test Interpretation: Etiological Screening for Recurrent Miscarriage

The following tests are core determinants for "whether IVF is possible and which type of IVF":

Test Item	Purpose	Key Interpretation
Chromosomal karyotype analysis of miscarriage tissue	Determine if the miscarriage was caused by a chromosomal abnormality	If abnormal karyotype (e.g., trisomy 16, 45,X), PGT-A is clearly indicated
Peripheral blood karyotype of both partners	Screen for structural abnormalities like balanced translocations, inversions	If abnormal, PGT-SR needed; if normal, continue investigating other factors
3D ultrasound of uterus / Hysteroscopy	Screen for uterine structural abnormalities	Septate uterus, polyps, adhesions, fibroids need treatment first
Antiphospholipid antibody panel	Screen for antiphospholipid syndrome	Positive requires immunotherapy + low molecular weight heparin anticoagulation
Thyroid function + antibodies	Screen for thyroid-related miscarriage	TSH controlled below 2.5 mIU/L, TPOAb positive requires attention
Coagulation panel + D-dimer	Screen for pre-thrombotic state	Abnormal requires anticoagulation therapy to avoid placental thrombosis
AMH + Antral follicle count	Assess ovarian reserve	Determines ovarian stimulation protocol and expected egg yield
Sperm DNA fragmentation index (DFI)	Assess male factor	DFI > 30% is associated with recurrent miscarriage and requires intervention

The more items missing from the above tests, the harder it is for the doctor to determine the suitability of PGT. It is recommended to complete all screenings 1-2 months before planning to travel to Georgia.

Module I: Actual Process

Standard IVF Process for Recurrent Miscarriage Patients in Georgia

Phase 1: Remote Medical Evaluation

• Submit all previous miscarriage records, surgical reports, pathology reports, and completed test results.
• A reproductive doctor in Georgia reviews the medical history to determine if IVF is indicated.
• If screening items are missing, they need to be completed locally or after arrival in Georgia.

Phase 2: Ovarian Stimulation and Egg Retrieval

• Individualized ovarian stimulation protocol (antagonist protocol or mild stimulation) based on AMH, age, and previous response.
• Starts on day 2-3 of menstruation, average stimulation duration 10-14 days.
• Egg retrieval performed under intravenous anesthesia, lasting approximately 15-20 minutes.

Phase 3: Embryo Culture and PGT Testing

• After fertilization, embryos are cultured to the blastocyst stage on day 5-6.
• Biopsy of trophectoderm cells (approximately 5-10 cells) from the blastocyst for PGT-A or PGT-SR.
• Testing period typically takes 14-21 days.

Phase 4: Frozen Embryo Transfer

• Select chromosomally euploid or low-level mosaic embryos for transfer.
• Endometrial preparation uses hormone replacement therapy or natural cycle.
• Blood test for hCG 12-14 days after transfer to confirm pregnancy.

Module J: Timeline

Overall Timeline: From Initial Consultation to Transfer

Phase	Time Required	Notes
Etiological screening (completing missing items)	1-2 months	Some tests have menstrual cycle requirements (e.g., antral follicle count, sex hormones)
Ovarian stimulation cycle	10-14 days	Must start during menstruation
Egg retrieval + Embryo culture	5-7 days	Requires 1-day hospital stay after retrieval
PGT testing	14-21 days	Endometrial preparation can be done simultaneously during waiting period
Frozen embryo transfer cycle	12-16 days	Requires monitoring of endometrial thickness and pattern
Total	3-5 months	Depends on screening completion and cycle synchronization

If the patient has completed all screenings in their home country, the shortest time from arrival in Georgia to transfer can be within 2 months.

Module G: Most Easily Overlooked Details

5 Most Easily Overlooked Details

• Miscarriage tissue not sent for chromosome analysis — Many patients do not have embryonic karyotype analysis after miscarriage, leaving doctors unable to determine if the miscarriage was due to chromosomal abnormalities, making the applicability of PGT questionable.
• Male partner's sperm DNA fragmentation index (DFI) not checked — Elevated DFI is directly linked to reduced embryo developmental potential and increased miscarriage rates, but is often attributed to "female factors."
• Lack of endometrial receptivity assessment — In some patients, recurrent miscarriage is related to a displaced window of implantation; ERA testing can optimize transfer timing.
• Chronic endometritis not screened — Asymptomatic chronic endometritis (CD138+) is a hidden cause of recurrent miscarriage, diagnosable by hysteroscopy + endometrial biopsy.
• Incomplete immune factor screening — Besides antiphospholipid antibodies, markers like NK cell activity and T cell subsets may be abnormal in some patients, but interpretation requires guidance from a specialist in reproductive immunology.

Module H: Most Common Pitfalls

5 Most Common Pitfalls

Module N: Special Situation Management

Special Situation Management Plans

Advanced Maternal Age Combined with Recurrent Miscarriage

For age ≥ 38 with ≥ 2 miscarriages, it is recommended to simultaneously assess mitochondrial DNA copy number (research technique) alongside PGT-A, but with the understanding that the predictive value of this test for live birth is not yet fully established. Additionally, older patients may have fewer eggs retrieved, necessitating mild stimulation protocols or cumulative cycle strategies.

Recurrent Miscarriage Despite PGT

Investigate the endometrial microbiome (dysbiosis), chronic endometritis (CD138+ cells), and consider ERA (Endometrial Receptivity Array) testing. Some patients may require laparoscopy to rule out endometriosis.

Diminished Ovarian Reserve (AMH < 1.0)

Natural cycle or mild stimulation protocols can be used, retrieving 1-3 eggs per cycle, accumulating embryos before unified PGT. Expectations must be managed: a low number of eggs may not yield a transferable euploid embryo.

One Partner Carries a Genetic Disease

Custom PGT-M probes are required, with a longer lead time (3-6 months). Some centers in Georgia collaborate with third-party genetic laboratories to complete single-gene embryo screening.

---

Closing: Doctor's Advice Entity Tags (Visual Knowledge Graph Coverage) Long-tail Keyword Natural Coverage Area